Pharmaceutical News

RSS

Xencor licenses its XmAb and Xtend technology platforms to Centocor Research & Development

Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation and biosuperior antibodies, announced today that it has licensed its XmAb® and Xtend™ technology platforms to Centocor Research & Development, Inc. for the optimization of Centocor’s antibody drug candidates.

30 Nov 2009

Bavarian Nordic to file a NDS for IMVAMUNE with Health Canada

Bavarian Nordic A/S announced today that the company expects to file a New Drug Submission (NDS) for its third-generation smallpox vaccine, IMVAMUNE(R) with the Canadian Authorities, Health Canada in 2010. If successful, this would be the first marketing approval of IMVAMUNE(R).

30 Nov 2009

Allos Therapeutics granted U.S. patent for FOLOTYN

Allos Therapeutics, Inc. today announced that the United States Patent and Trademark Office has issued a patent for the use of FOLOTYN™ (pralatrexate injection) for the treatment of T-cell lymphoma. U.S. Patent No. 7,622,470 was issued to Memorial-Sloan Kettering Cancer Center, SRI International and Southern Research Institute, and expires on November 24, 2025.

30 Nov 2009

Eli Lilly's Cymbalta receives FDA approval

The U.S. Food and Drug Administration (FDA) has approved Cymbalta® (duloxetine HCl) for the maintenance treatment of generalized anxiety disorder (GAD) in adults, announced Eli Lilly and Company (NYSE: LLY).

30 Nov 2009

Cell Therapeutics' platinum-based anti-tumor compounds demonstrate stronger anti-tumor potency

Cell Therapeutics, Inc. (CTI) announced today that its new class of platinum-based anti-tumor compounds, termed bis-platinates, demonstrated a stronger anti-tumor potency and activity compared to currently available platinum-based compounds as well as the ability to overcome cisplatin-resistance in cancer cell lines.

30 Nov 2009

CCAC congratulates the Ontario government for expanding access to Avastin

The Colorectal Cancer Association of Canada (CCAC) applauds the Ontario Ministry of Health and Long-Term Care's decision today to provide expanded access of Avastin (bevacizumab) to patients with metastatic colorectal cancer.

30 Nov 2009

PanGenex expects release of television program on Calci-CLEAR dietary supplement

PanGenex Corporation announced today that it anticipates the release of its long form television program, demonstrating the benefits of Calci-CLEAR™, its patent pending dietary supplement that addresses soft tissue calcification, pursuant to its partnership with Incredible Discoveries® in early 2010.

28 Nov 2009

EMEA determines MAA for omacetaxine mepesuccinate for treatment of CML patients

ChemGenex Pharmaceuticals Limited announced today that the European Medicines Agency ("EMEA") has determined that the Marketing Authorization Application ("MAA") for omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia (CML) patients who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation is valid.

28 Nov 2009

Cromoz's new drug delivery system to reduce amount of drugs used in cancer treatment

Cromoz Inc., located in Research Triangle Park, will initiate water-soluble carbon nanotube-based cancer drug delivery system in Hyderabad, India. The water-soluble carbon nanotubes, which have functional groups on the walls that allows for conjugation with cancer drugs, was developed in partnership with the Indian Institute of Kanpur (ITT). The conjugated carbon nanotubes serves as a drug delivery vehicle with the ability to target the cancer site which has the potential to increase the drug efficacy.

28 Nov 2009

Agriflu approved to prevent diseases caused by influenza virus subtypes A and B

The U.S. Food and Drug Administration today approved Agriflu for people ages 18 years and older to prevent disease caused by influenza virus subtypes A and B.

27 Nov 2009

Rights Issue to be carried out by keeping the authorization by the Annual General Meeting, resolves Tripep

The Board of Directors of Tripep AB (publhas on the 27th of November 2009, based on the authorization by the Annual General Meeting resolved to carry out a rights issue.

27 Nov 2009

Stallergenes granted European approval to market Oralair

Stallergenes has been granted European approval to market Oralair(R) in both adults and children through a Mutual Recognition Procedure. Germany, the first country where Oralair(R) has been marketed, was the reference Member state.

27 Nov 2009

European Commission approves MICARDIS medication for CV protection

MICARDIS® is the first treatment in its class to be approved for this indication. The EMEA approval is the second major milestone for MICARDIS® in cardiovascular protection. It follows the approval by the US FDA for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors.

27 Nov 2009

Health Canada announces recent changes made to heparin manufacturing standards

Health Canada is informing health care professionals and Canadians of recent changes to heparin manufacturing standards in the United States that will result in a decrease in the potency of certain heparin products by about 10 per cent.

27 Nov 2009

NCKU, ScinoPharm Taiwan sign MOU to establish university-industry cooperation

National Cheng Kung University (NCKU), Taiwan signed a MOU with ScinoPharm Taiwan Ltd. on Nov. 24th.

27 Nov 2009

Copper sequestering drug tetrathiomolybdate shown to be effective in treating Wilson disease

The copper sequestering drug tetrathiomolybdate (TM) has been shown in studies to be effective in the treatment of Wilson disease, a disease caused by an overload of copper, and certain metastatic cancers.

27 Nov 2009

Risk of postnatal transmission can be reduced with HAART in HIV-positive mothers

Researchers conducting clinical trials in Rwanda have concluded that the risk of postnatal transmission is minimal in HIV-positive mothers undergoing highly active antiretroviral therapy (HAART) while breastfeeding.

27 Nov 2009

ALDA Pharmaceuticals and Shoppers Drug Mart sign distribution agreement

ALDA Pharmaceuticals Corp. (TSX VENTURE:APH)(OTCBB:APCSF) ("the Company" or "ALDA") announces that it has entered into an agreement with Shoppers Drug Mart Corporation ("Shoppers") that will make the Company's T36® Antiseptic Hand Sanitizer available in over 1,170 Shoppers Drug Mart and Pharmaprix stores across Canada.

26 Nov 2009

MICARDIS receives Health Canada approval to reduce the risk of non-fatal stroke

MICARDIS(R) (telmisartan) has received Health Canada approval to reduce the risk of non-fatal stroke or non-fatal myocardial infarction in patients 55 years or older at high risk of developing major cardiovascular events who cannot tolerate an angiotensin converting enzyme (ACE) inhibitor.

26 Nov 2009

OSEO awards fund for Galapagos NV's antibody therapeutics program

Galapagos NV announces that its antibody therapeutics program with MorphoSys and SARM program have been awarded funding by the French governmental organization OSEO.

26 Nov 2009

Pharmaceutical News

Xencor licenses its XmAb and Xtend technology platforms to Centocor Research & Development

Bavarian Nordic to file a NDS for IMVAMUNE with Health Canada

Allos Therapeutics granted U.S. patent for FOLOTYN

Eli Lilly's Cymbalta receives FDA approval

Cell Therapeutics' platinum-based anti-tumor compounds demonstrate stronger anti-tumor potency

CCAC congratulates the Ontario government for expanding access to Avastin

PanGenex expects release of television program on Calci-CLEAR dietary supplement

EMEA determines MAA for omacetaxine mepesuccinate for treatment of CML patients

Cromoz's new drug delivery system to reduce amount of drugs used in cancer treatment

Agriflu approved to prevent diseases caused by influenza virus subtypes A and B

Rights Issue to be carried out by keeping the authorization by the Annual General Meeting, resolves Tripep

Stallergenes granted European approval to market Oralair

European Commission approves MICARDIS medication for CV protection

Health Canada announces recent changes made to heparin manufacturing standards

NCKU, ScinoPharm Taiwan sign MOU to establish university-industry cooperation

Copper sequestering drug tetrathiomolybdate shown to be effective in treating Wilson disease

Risk of postnatal transmission can be reduced with HAART in HIV-positive mothers

ALDA Pharmaceuticals and Shoppers Drug Mart sign distribution agreement

MICARDIS receives Health Canada approval to reduce the risk of non-fatal stroke

OSEO awards fund for Galapagos NV's antibody therapeutics program

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Latest News